GLP-1RA治疗阻塞性睡眠呼吸暂停综合征的研究进展
Research progress on the treatment of obstructive sleep apnea syndrome with GLP-1RA
罗怡 1袁璐 1马建华1
作者信息
- 1. 南京医科大学附属南京医院(南京市第一医院)内分泌科,南京 210012
- 折叠
摘要
阻塞性睡眠呼吸暂停综合征是一种常见的慢性睡眠障碍,其特征是睡眠时上呼吸道间歇性变窄导致气道部分或完全关闭.肥胖是其发生和恶化的主要因素,患者可合并全身炎症、胰岛素抵抗、2型糖尿病和心血管疾病等,临床上还没有针对该病的治疗药物.胰高血糖素样肽-1受体激动剂不仅可以使这类患者体重下降,还能改善其诸多并发症.本文对胰高血糖素样肽-1受体激动剂在阻塞性睡眠呼吸暂停综合征中的疗效进行综述.
Abstract
Obstructive sleep apnea syndrome(OSAS)is a common chronic sleep disorder character-ized by episodic narrowing of the upper airway during sleep leading to partial or complete airway closure.0-besity is one of the main factors in its occurrence and deterioration,and patients often have systemic inflam-mation,insulin resistance,type 2 diabetes and cardiovascular disease,etc.However,there is no clinical drug for treating OSAS.Glucagon-like peptide-1 receptor agonists(GLP-1RA)not only perform well in weight loss,but also improve many comorbidities of OSAS.Therefore,this paper reviews the effects of GLP-1RA on OSAS.
关键词
胰高血糖素样肽-1受体激动剂/阻塞性睡眠呼吸暂停综合征/肥胖Key words
Glucagon-like peptide-1 receptor agonists/Obstructive sleep apnea syndrome/Obesity引用本文复制引用
出版年
2024
NETL
NSTL
万方数据